Early Weight Regain After Gastric Bypass Does Not Affect Insulin Sensitivity But Is Associated with Elevated Ghrelin

Robyn A. Tamboli1, Igal Breitman1, Pam A. Marks-Shulman1, Kareem Jabbour1, Willie Melvin1, Brandon Williams1, Ronald H. Clements1, Irene D. Feurer1,2, and Naji N. Abumrad1

Objectives: We sought to determine: (1) if early weight regain between 1 and 2 years after Roux-en-Y gastric bypass (RYGB) is associated with worsened hepatic and peripheral insulin sensitivity, and (2) if preoperative levels of ghrelin and leptin are associated with early weight regain after RYGB.

Methods: Hepatic and peripheral insulin sensitivity and ghrelin and leptin plasma levels were assessed longitudinally in 45 subjects before RYGB and at 1 month, 6 months, 1 year, and 2 years postoperatively. Weight regain was defined as ≥5% increase in body weight between 1 and 2 years after RYGB.

Results: Weight regain occurred in 33% of subjects, with an average increase in body weight of 10 ± 5% (8.5 ± 3.3 kg). Weight regain was not associated with worsening of peripheral or hepatic insulin sensitivity. Subjects with weight regain after RYGB had higher preoperative and postoperative levels of ghrelin compared to those who maintained or lost weight during this time. Conversely, the trajectories of leptin levels corresponded with the trajectories of fat mass in both groups.

Conclusions: Early weight regain after RYGB is not associated with a reversal of improvements in insulin sensitivity. Higher preoperative ghrelin levels might identify patients that are more susceptible to weight regain after RYGB.

Obesity (2014) 22, 1617-1622. doi:10.1002/oby.20776

Introduction

Bariatric surgery is the most effective weight loss approach for obesity. Patients undergoing Roux-en-Y gastric bypass (RYGB) surgery lose approximately 60% of excess body weight in 2 years (1). This amount of weight loss is not typically achieved or sustained with lifestyle or pharmacological interventions. RYGB is also associated with increased recovery and decreased mortality from numerous chronic obesity-related comorbidities (2,3). Recent randomized trials demonstrate that bariatric surgery is more effective than conventional medical therapy for achieving glycemic control in patients with type 2 diabetes over the course of a year (4,5). RYGB also improves the hepatic and peripheral insulin resistance (6,7) which develops with weight gain and predisposes individuals to type 2 diabetes (8).

Weight regain and surgical weight-loss “failure” have been reported to occur in a subset of patients 5-10 years after RYGB (9-13). It is unknown if weight regain is detrimental to the substantial metabolic improvements that occur after RYGB. Weight regain after RYGB may be benign, given that some of the beneficial metabolic effects of RYGB are considered to be weight-loss independent. The severe caloric restriction that occurs immediately after RYGB has beneficial effects on hepatic insulin sensitivity (14-16); however, weight regain could imply an increased caloric intake and, as a result, lead to worsened hepatic insulin sensitivity. Conversely, the improvement in peripheral insulin sensitivity after RYGB is weight-loss dependent (17) and, therefore, might also be negatively affected by weight regain after RYGB. Impaired insulin action occurs early in the natural history of diabetes (8); thus, worsened insulin sensitivity with weight regain after RYGB could be a significant contributor to relapse of type 2 diabetes.

It would be of great clinical value to determine which patients are at risk to regain weight early after RYGB to focus more intensive follow-up treatment and counseling in this patient population.

1 Department of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee. Correspondence: Naji N. Abumrad (naji.abumrad@vanderbilt.edu) or Robyn A. Tamboli (robyn.tamboli@vanderbilt.edu) 2 Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee

Funding agencies: This research was supported by the following grants from the National Institutes of Health: DK070860 and DK091748 to N.N.A.; UL1TR000445 (Vanderbilt Clinical and Translational Science Award); DK020593 and DK059637 (Vanderbilt Diabetes Research and Training Center); DK058404 (Vanderbilt Digestive Disease Research Center).

Disclosure: The authors declared no conflicts of interest.

Author contributions: R.A.T. acquired, analyzed and interpreted data, performed statistical analyses, and wrote the manuscript; I.B. analyzed and interpreted data; P.A.M-S. acquired data and provided administrative support; K.J. acquired data; W.M. acquired data; B.W. acquired data; R.H.C. acquired data; I.D.F. performed and interpreted statistical analyses and edited the manuscript; N.N.A. designed and supervised the experiments, interpreted data, and edited the manuscript. All authors critically revised and approved the manuscript. N.N.A. is the guarantor of the study.

Received: 29 January 2014; Accepted: 14 April 2014; Published online 29 April 2014. doi:10.1002/oby.20776
Relatively few studies have addressed this issue. Analysis of 11 obesity-related genes failed to find a relationship with weight regain after bariatric surgery (18), but the potential involvement of other genes in the durability of surgical weight loss remains to be determined. Alterations in peptides that regulate energy balance, such as leptin and ghrelin, have been shown to predict weight regain after diet-induced weight loss (19). Decreased plasma levels of the orexigenic hormone ghrelin have been proposed to contribute to the weight-loss effects of RYGB (20).

The objectives of this study were to determine: (1) if early weight regain between 1 and 2 years after RYGB is detrimental to hepatic and peripheral insulin sensitivity, and (2) if preoperative levels of ghrelin and leptin are associated with early weight regain after RYGB.

Methods
Participants
Written informed consent was obtained from all participants prior to the study, which was approved by the Vanderbilt University Institutional Review Board. Participants were recruited from the Vanderbilt Center for Surgical Weight Loss after approval for RYGB. This study was initiated as a randomized trial to determine the effect of surgical removal of the omentum at the time of RYGB surgery on insulin sensitivity. After we reported that omentectomy provided no additional benefit to RYGB at 1 year after surgery (6,7), enrollment was terminated, and we continued to follow participants to explore the long-term effects of RYGB on insulin sensitivity. Participants with both a 1 year and 2 years postoperative study visit (n = 45) were included in the analyses of weight regain.

Study procedures
All study visits (preoperative and at 1 month, 6 months, 1 year, and 2 years post-RYGB) were conducted at the Vanderbilt Clinical Research Center from March 2005 to October 2011. Oral anti-diabetic agents and long-acting insulin were discontinued for 5 days prior to each study visit. Measurements of body composition by dual x-ray absorptiometry and steady-state glucose turnover by hyperinsulinemic-euglycemic clamp with glucose isotope infusion were performed preoperatively, and 1 month, 6 months, 1 year, and 2 years post-RYGB. Steady-state plasma insulin levels achieved during the clamp decreased over time (pre-RYGB, 2.9 μU ml⁻¹; 1 month, 338 μU ml⁻¹; 1 year, 338 μU ml⁻¹; and 2 years, 3.3 μU ml⁻¹). Weight regain was defined as ≥5% increase in body weight between postoperative years 1 and 2; the remainder of the participants was classified as having maintained/lost weight. This threshold was selected to define weight regain in our cohort because a weight loss of 5-10% is recommended to improve obesity-related metabolic comorbidities (24,25).

Statistical analyses
Study data were managed using REDCap electronic data capture tools hosted at Vanderbilt. Exploratory analyses were conducted to examine frequency distributions of key measures. Independent sample t-tests and chi-squared tests were used to compare baseline measures between weight groups (regain or maintain/lose). The effect of time on weight and metabolic outcome measures was tested using linear mixed effects models with Bonferroni adjustments for multiple comparisons. Separate mixed effects models, each including two main effects (time and diabetes or time and weight regain group) and an interaction effect (time by diabetes or time by weight regain group) were used to determine whether weight regain (regain or maintain/lose) and preoperative diabetes (yes or no) were associated with differing trajectories over time of fat mass, lean mass, peripheral and hepatic insulin sensitivity, leptin, and ghrelin. If an interaction effect was statistically significant, parameter estimates for individual interaction contrasts were interpreted to identify specific time points between which trajectories differed. If an overall interaction effect was not statistically significant, time point-specific trajectories were not examined further. Each mixed effects model included all available data for each time point. Secondary mixed effects models that held percent change in weight between years 1 and 2 as a continuous covariate were tested to evaluate findings in relation to the primary models (which treated weight change as a dichotomous factor—regain or maintain/lose). This approach preserved maximum statistical power while systematically examining the association of weight change between years 1 and 2 with the complete temporal course of body composition and metabolic measures. All analyses were performed using IBM SPSS Statistics software.

Results
Longitudinal assessment of weight loss and insulin sensitivity within 2 years after RYGB
Over the 2-year follow-up period, RYGB resulted in significant weight loss (Table 1). Hyperinsulinemic-euglycemic clamps with glucose isotope infusion were performed preoperatively, and 1 month, 6 months, 1 year, and 2 years post-RYGB. Steady-state plasma insulin levels achieved during the clamp decreased over time (pre-RYGB, 362 ± 155 μU ml⁻¹; 1 month, 338 ± 124 μU ml⁻¹; 6 months,
Obesity

305 ± 125 μU ml⁻¹; 1 year, 303 ± 126 μU ml⁻¹; and 2 years, 293 ± 108 μU ml⁻¹; P = 0.029). Both peripheral and hepatic insulin sensitivity improved significantly during the initial 2 years after RYGB, but with different temporal trajectories (Table 1). Peripheral insulin sensitivity (M/I) did not change at 1-month post-RYGB, increased up to 1 year, and stabilized thereafter. HSI improved within the first month after surgery, further increased at 6 months, and then remained stable. A diagnosis of type 2 diabetes by a primary care physician was present in 49% (22/45) of subjects before surgery. Anti-diabetes therapy for these subjects included (number of participants): diet (1); insulin only (1); one oral medication (9); two oral medications (6); or three oral medications (5). At 2 years after RYGB, only one subject remained on diabetes therapy (insulin + metformin). Postoperative improvements in weight, BMI, HSI, or M/I over the first 2 years following RYGB were not significantly different between participants with and without a preoperative diagnosis of type 2 diabetes (all group by time interaction effects P ≥ 0.672, data not shown).

Weight regain occurs between 1 and 2 years after RYGB

During the first year after RYGB, all participants continued to lose weight or were weight stable. Although the mean weight of the participants remained stable between 1 and 2 years post-RYGB, there was variability in individual weight trajectories during this period. Values for percent weight change between years 1 and 2 were normally distributed and ranged from −17% to 22%. A weight gain of ≥5% occurred in 33% of the cohort (the upper tertile) between postoperative years 1 and 2, with an average increase in body weight of 10% ± 5%. This represents a weight regain of 8.5 ± 3.3 kg and 22 ± 9% of the weight lost during the first postoperative year. The gain in body weight consisted primarily of fat mass and not lean mass (Figure 1A and 1B). There was no significant difference in preoperative age, sex, type 2 diabetes, BMI, or weight between those participants that regained weight and those that maintained or continued to lose weight (Table 2).

Early weight regain does not affect insulin sensitivity after RYGB

We hypothesized that those participants with weight regain between 1 and 2 years post-RYGB would experience a deterioration of insulin sensitivity. Although peripheral and hepatic insulin sensitivity increased significantly over time (both P < 0.001), there was no difference between the weight regain and maintain/lose groups in the trajectories of peripheral insulin sensitivity (Figure 1C; group by time interaction P = 0.191) or hepatic insulin sensitivity (Figure 1D; group by time interaction P = 0.137). Secondary analyses, which treated percent weight change between years 1 and 2 as a continuous covariate, were completely consistent with these findings.

High preoperative ghrelin levels are associated with early weight regain after RYGB

Ghrelin and leptin are appetite-related hormones with opposing actions; ghrelin is orexigenic and leptin is anorexigenic. Given the role of these hormones in the regulation of food intake, we sought to determine if ghrelin or leptin levels were associated with early weight regain after RYGB. Subjects with ≥5% weight regain between postoperative years 1 and 2 had significantly higher preoperative levels of total ghrelin than those who maintained or lost weight during this period (Table 2). Figure 1F shows that the weight regain group maintained these higher levels of ghrelin after surgery (main effect of group P = 0.014, group by time interaction effect P = 0.707). Preoperative ghrelin levels were related to the trajectories of weight and BMI after RYGB (preoperative ghrelin by time interaction effects, P ≤ 0.001). Baseline plasma leptin levels did not differ between the weight regain and maintain/lose group (Table 2). Leptin levels were decreased overall after RYGB (P < 0.001), but increased in the weight regain group between 1 and 2 years post-RYGB (overall interaction P = 0.011, 1-2 years interaction contrast P = 0.017) (Figure 1E). The trajectories of leptin levels corresponded with fat mass (Figure 1A). Secondary analyses, which treated percent weight change between years 1 and 2 as a continuous covariate, were completely consistent with these findings.

Discussion

Overall, the subjects in our cohort of bariatric surgery patients experienced significant weight loss up to 2 years after surgery, consisting of losses in both lean and fat tissue. Although, on average, subjects
Weight regain at 2 years after RYGB is not associated with worsened insulin sensitivity, but is associated with elevated plasma ghrelin levels. Weight regain was defined as ≥5% weight change between 1 and 2 years after RYGB, and occurred in 33% of the cohort. Trajectories of fat (A) and lean (B) mass losses were similar between groups up to 1 year after RYGB. There was no effect of weight regain on peripheral (C) or hepatic (D) insulin sensitivity (both group by time interaction $P > 0.137$). Leptin levels (E) increased between 1 and 2 years after RYGB in the weight regain group (group by time interaction $P = 0.011$). Ghrelin levels (F) were higher in the weight regain group at baseline ($P = 0.009$) and this stratification was maintained over time (group by time interaction $P = 0.707$). Data are mean ± SEM.

Figure 1 Weight regain at 2 years after RYGB is not associated with worsened insulin sensitivity, but is associated with elevated plasma ghrelin levels. Weight regain was defined as ≥5% weight change between 1 and 2 years after RYGB, and occurred in 33% of the cohort. Trajectories of fat (A) and lean (B) mass losses were similar between groups up to 1 year after RYGB. There was no effect of weight regain on peripheral (C) or hepatic (D) insulin sensitivity (both group by time interaction $P > 0.137$). Leptin levels (E) increased between 1 and 2 years after RYGB in the weight regain group (group by time interaction $P = 0.011$). Ghrelin levels (F) were higher in the weight regain group at baseline ($P = 0.009$) and this stratification was maintained over time (group by time interaction $P = 0.707$). Data are mean ± SEM.
TABLE 2 Baseline characteristics of subjects with and without weight regain between 1 and 2 years after RYGB

|                          | Regain | Maintain/lose | P value |
|--------------------------|--------|---------------|---------|
| n                        | 15     | 30            | -       |
| Age (years)              | 43 ± 10| 44 ± 9        | 0.882   |
| Female (%)               | 93     | 87            | 0.651   |
| T2D (%)                  | 47     | 50            | 0.999   |
| BMI (kg m⁻²)             | 47 ± 9 | 50 ± 11       | 0.346   |
| Weight (kg)              | 127 ± 30| 138 ± 25     | 0.182   |
| Fat mass (kg)            | 62 ± 15| 65 ± 14       | 0.574   |
| Lean mass (kg)           | 59 ± 13| 65 ± 11       | 0.137   |
| M/I                      | 19 ± 10| 16 ± 11       | 0.354   |
| HISI                     | 0.5 ± 0.3| 0.4 ± 0.2  | 0.103   |
| Leptin (ng ml⁻¹)         | 39 ± 9 | 41 ± 16       | 0.587   |
| Ghrelin (pg ml⁻¹)        | 722 ± 290| 540 ± 156    | 0.009   |

HISI, hepatic insulin sensitivity index; M/I, peripheral insulin sensitivity; T2D, type 2 diabetes. Data are mean ± SD.

were still obese 2 years after surgery, they experienced significant and sustained improvements in hepatic and peripheral insulin sensitivity. A strength of our study is the longitudinal measurement of tissue-specific insulin sensitivity using the gold-standard technique, the hyperinsulinemic-euglycemic clamp, in a relatively large cohort of subjects for this technique. Our assessments demonstrate that hepatic insulin sensitivity improves within the first month after surgery, while peripheral insulin sensitivity does not improve until after the first postoperative month. This suggests that, in the extremely obese, hepatic insulin sensitivity improves with reduced nutrient intake and small amounts of weight loss, while a more significant weight loss may be required to affect skeletal muscle insulin sensitivity. Based on these findings, we anticipated that early weight regain after RYGB may be detrimental to insulin sensitivity, and hepatic insulin sensitivity in particular.

Several studies have indicated that some patients experience weight regain after RYGB (9-13). It is not uncommon for 20-25% of initial weight loss to be regained by 10 years postoperatively (26). There is no strict definition of weight-loss maintenance, although a weight change of less than 3% has been proposed for diet-induced weight loss (27). A weight increase of 5 kg has been proposed (28) or used (29) to indicate weight regain after bariatric surgery or diet-induced weight loss (30). Because a weight loss of 5-10% is recommended to improve obesity-related metabolic comorbidities (24,25), we selected a weight increase of 5% or more as a threshold to assess the impact of weight regain on insulin sensitivity. In our cohort, one-third of participants experienced a 10 ± 5% weight regain between postoperative years 1 and 2. This represents a regain of approximately 8 kg and 20% of the weight loss that was achieved in the first year after RYGB. Thus, the participants categorized as having weight regain in our study are encompassed by all the aforementioned criteria for weight regain.

A major question among clinicians and patients alike is whether failure to maintain weight loss after RYGB will lead to recurrence of obesity-related comorbidities. Our data indicate that a weight regain of at least 5% incurred between the first and second postoperative years is not associated with reductions in either peripheral or hepatic insulin sensitivity. This is a significant finding because impaired insulin sensitivity is characteristic of conversion to pre-diabetes (8). Several recent studies explored the durability of type 2 diabetes remission after RYGB (31-33). Arterburn et al., in a recent retrospective cohort study of nearly 4500 RYGB cases, reported that one-third of patients experienced relapse of type 2 diabetes within 5 years of initial remission (31). Only a limited number of studies have examined the effect of RYGB weight recidivism on the durability of type 2 diabetes remission, and found that weight regain was a significant predictor of type 2 diabetes recurrence (32-35). The mean follow-up time for these studies ranged from 3 to 8.8 years. It remains possible that a longer follow-up time in our cohort would reveal a negative relationship between weight regain and insulin sensitivity. Although it is important to better understand the long-term durability of metabolic improvements after RYGB, it still remains the most effective means to achieve glycemic control in type 2 diabetes (4,5).

Ghrelin and leptin have opposing roles in regulation of energy balance: ghrelin increases and leptin decreased food intake (36). Elevated ghrelin levels after diet-induced weight loss have been proposed to explain the difficulty in attaining and maintaining weight loss (20,37). Conversely, decreased ghrelin levels after RYGB are proposed to underlie some of the effectiveness of this surgical procedure to reduce food intake and induce weight loss (20). We did not find a relationship between postoperative ghrelin levels and overall degree of weight loss at 1 and 2 years after RYGB (data not shown). However, we demonstrate that higher preoperative and postoperative ghrelin levels are associated with early weight regain after RYGB. In contrast, levels of the anorexic hormone leptin followed the groups’ weight trajectories. This suggests that ghrelin does not impact degree of initial weight loss, but rather maintenance of surgical weight loss. It is important to note that we assessed total ghrelin levels, which provides a composite measure of the two circulating forms of ghrelin: acyl ghrelin and des-acyl ghrelin. Acyl ghrelin is predominately considered the form that mediates the effects of ghrelin to increase food intake and adiposity via interaction with the growth hormone secretagogue receptor (38). However, rodent studies suggest that desacyl ghrelin also functions to increase food intake and adiposity (39,40). Thus, the relative contributions of acyl and desacyl ghrelin to the regulation of body weight are unclear at present.

We recognize several potential limitations of this study. The size of the cohort and predominance of females limit the generalization of the findings. Even though the cohort included subjects with and without preoperative type 2 diabetes, both groups experienced comparable improvements in insulin sensitivity after RYGB. Our study lacked information regarding whether post-prandial metabolic responses (e.g., insulin secretion, the incretin effect, and ghrelin suppression) are influenced by weight regain. Since this study was designed to evaluate the metabolic responses to RYGB, we were unable to assess the influence of genetic and psychosocial factors on weight loss outcomes after RYGB. Regardless, these findings indicate that early weight regain does not adversely affect insulin sensitivity after RYGB. Importantly, we report that preoperative ghrelin levels might identify those patients more susceptible to weight regain after RYGB and should receive more intense post-surgical follow-up to prevent post-RYGB weight recidivism. Additional studies in larger cohorts with longer postoperative follow up are
necessary to fully appreciate the impact of weight regain on the durability of metabolic improvements after RYGB.

Acknowledgments

The authors appreciate participants who volunteered for this study and thank the following Vanderbilt colleagues for invaluable assistance in conducting these studies: Phil Williams, Erik N. Hansen, James M. Isbell, Jabbar Saliba, and the CRC nurses.

© 2014 The Obesity Society

References

1. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-1737.
2. Sjostrand L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-2693.
3. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-761.
4. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794.
5. Freire RH, Borges MC, Alvarez-Leite JI, Toulson Davison Correia ML. Food quality, physical activity, and nutritional follow-up as determinant of weight regain after Roux-en-Y gastric bypass. Nutrition 2012;28:53-58.
6. Topart P, Becouarn G, Ritz P. Weight loss is more sustained after biliopancreatic diversion with duodenal switch than Roux-en-Y gastric bypass in superobese patients. Surg Obes Relat Dis 2013;9:526-530.
7. Christon NV, Look D, Maclean LD. Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2006;244:734-740.
8. Zucker IH, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794.
9. Freire RH, Borges MC, Alvarez-Leite JI, Toulson Davison Correia ML. Food quality, physical activity, and nutritional follow-up as determinant of weight regain after Roux-en-Y gastric bypass. Nutrition 2012;28:53-58.
10. Topart P, Becouarn G, Ritz P. Weight loss is more sustained after biliopancreatic diversion with duodenal switch than Roux-en-Y gastric bypass in superobese patients. Surg Obes Relat Dis 2013;9:526-530.
11. Barbash AS, Zardo M, Padoin AV, et al. Excess weight loss variation in late postoperative period of gastric bypass. Obes Surg 2010;20:1479-1483.
12. Christon NV, Look D, Maclean LD. Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2006;244:734-740.
13. Magnino G, Porta G, Fazio R, et al. Long-term weight regain after gastric bypass: a 4-year prospective study. Obes Surg 2008;18:648-651.
14. Jazet IM, Pijl H, Frollich M, Romijn JA, Meinders AE. Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin. Metabolism 2005;54:705-712.
15. Kirk E, Reeds DN, Finck BN, Mayyurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009;136:1552-1560.
16. Christiansen MP, Linfoot PA, Neese RA, Hellerstein MK. Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes. Diabetes 2000;49:1691-1699.
17. Campos GM, Rabl C, Peeva S, et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg 2010;14:15-23.
18. Sarzynski MA, Jacobsen P, Rankinen T, et al. Associations of markers in 11 obesity candidate genes with maximal weight loss and weight regain in the SOS bariatric surgery cases. Int J Obes (Lond) 2011;35:676-683.
19. Cruejeiras AB, Goyenechea E, Abete I, et al. Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J Clin Endocrinol Metab 2010;95:5037-5044.
20. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-1630.
21. Tamboli RA, Hossain HA, Marks PA, et al. Body composition and energy metabolism following Roux-en-Y gastric bypass surgery. Obesity (Silver Spring) 2010;18:1718-1724.
22. Hatoum JI, Kaplan LM. Advantages of percent weight loss as a method of reporting weight loss after Roux-en-Y gastric bypass. Obesity (Silver Spring) 2013;21:1519-1525.
23. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470.
24. Klein S. Outcome success in obesity. Obes Res 2001;9 Suppl 4:S345-358S.
25. Wing RR, Lag W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabet Med 2011;34:1481-1486.
26. Heber D, Greenway FL, Kaplan LM, Livingston E, Salvador J, Still C. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010;95:4823-4843.
27. Stevens J, Trueblood KF, McClain JE, Cai J. The definition of weight maintenance. Int J Obes (Lond) 2006;30:391-399.
28. Johnson Stoklosa C, Atwal S. Nutrition Care for Patients with Weight Regain after Bariatric Surgery. Gastroenterol Res Pract 2013;2013:256145.
29. Bond DS, Phelan S, Leachey TM, Hill JO, Wing RR. Weight-loss maintenance in successful weight losers: surgical vs non-surgical methods. Int J Obes (Lond) 2009;33:173-180.
30. Camps SG, Verhoeef SP, Westerterp KR. Weight loss, weight maintenance, and adaptive thermogenesis. Am J Clin Nutr 2013;97:990-994.
31. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93-102.
32. Chikangwe SW, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010;6:254-259.
33. DiGiorigi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 2010;6:249-253.
34. Jimenez A, Casamitjana R, Flores L, et al. Long-term effects of sleeve gastrectomy on the natural history of type 2 diabetes. Diabetes Care 2013;36:122-131.
35. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007;8:21-34.
36. Hansen TK, Dall R, Hosoda H, et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 2002;56:203-206.
37. Toshinai K, Yamaguchi H, Sun Y, et al. Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology 2006;147:2306-2314.